Market news

Despite revenue decline and regulatory hurdles, Dr Reddy's Laboratories Ltd (RDY) focuses on strategic growth in emerging markets and innovation.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.

Dr. Reddy's Laboratories (NYSE:RDY) reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide API-related challenges weighed on results. Management said the company’s base business, excluding lenalidomi

July 23 (Reuters) - Shares of Dr Reddy's Laboratories fell as much as 6.9% on Thursday after many brokerages cut their earnings forecasts for the Indian drugmaker following weaker-than-expected

Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety